Clinical Trials in Washington

Showing 2841-2860 of 9,462 trials

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

NCT05039177

* To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination with other cancer therapies in study participants with advanced GI malignancies. * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 administered in combination with other cancer therapies. * To evaluate the antitumor activity of ERAS-007 in combination with other cancer therapies. * To evaluate the PK profiles of ERAS-007 and other cancer therapies when administered in combination.

Metastatic Colorectal CancerMetastatic Pancreatic Ductal Adenocarcinoma

Erasca, Inc.102 participantsStarted Sep 2021

Birmingham, Alabama, United States • Duarte, California, United States • Orange, California, United States +11 more locations

COMPLETEDPhase 142 miles

A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors

NCT02667873

Study SL-801-0115 is a dose-escalation study evaluating multiple doses and schedules of orally administered SL-801 in participants with advanced solid tumors.

Solid Tumors

Stemline Therapeutics, Inc.72 participantsStarted Feb 2016

New Haven, Connecticut, United States • Sarasota, Florida, United States • Nashville, Tennessee, United States +3 more locations

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors

Find Trials by Condition in Washington

NB-001 in Children and Adolescents With 22q11 Deletion Syndrome

A Food Additive Removal Diet for Pediatric Eosinophilic Esophagitis

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

Open-Label Study of Setmelanotide in Hypothalamic Obesity

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)

The Community Youth Development Study: A Test of Communities That Care

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity

Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).

Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

A Study of Imvotamab in Severe Systemic Lupus Erythematosus

Foot and Ankle Post-operative Oedema Management Using Geko™